Phase 3Recruiting
A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma
A Phase 3 Randomized Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma
- Sponsor
- Qilu Pharmaceutical Co., Ltd. (Industry)
- Enrollment
- 228 planned
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- QLS32015; Pomalidomide; Selinexor; Dexamethasone
- Ages
- adults, older adults
- Registry
- NCT07138209
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to compare the safety and efficacy of QLS32015 with Pd/Sd for the treatment of relapsed or refractory multiple myeloma.
Primary outcomes
- Progression-free Survival (PFS)
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered